BioLineRx (BLRX) Share-based Compensation (2014 - 2026)
BioLineRx (BLRX) posted quarterly Share-based Compensation of $48000.0 for Q4 2025, up 131.17% year-over-year from $20764.0 in Q4 2024, and down 52.48% quarter-over-quarter from $101000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Share-based Compensation (2014 - 2026) Analysis & Trends
BioLineRx's Share-based Compensation history runs 12 years deep, the most recent figure standing at $48000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation rose 131.17% year-over-year to $48000.0; the TTM figure through Dec 2025 stood at $396000.0 (down 65.11% YoY), while the FY2025 annual figure was $396000.0, down 65.11% from the prior year.
- Share-based Compensation for Q4 2025 stood at $48000.0, down from $101000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.0 million in Q4 2022, with the low at -$154000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $376000.0 (2021), against an average of $379600.0.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 167.26% in 2022, then sank 116.58% in 2024.
- BioLineRx's Share-based Compensation stood at $391000.0 in 2021, then surged by 167.26% to $1.0 million in 2022, then retreated by 11.1% to $929000.0 in 2023, then tumbled by 116.58% to -$154000.0 in 2024, then surged by 131.17% to $48000.0 in 2025.
- Business Quant data shows BLRX's Share-based Compensation at $48000.0 in Q4 2025, $101000.0 in Q3 2025, and $53000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 41.25 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 | 79,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79,000.00 |
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 48,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Jun 30, 2023 | 485,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 614,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Mar 31, 2022 | 256,000.00 |
| Dec 31, 2021 | 391,000.00 |
| Sep 30, 2021 | 272,000.00 |